A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.
Inclusion Criteria:
Exclusion Criteria:
Los Angeles, California 90033, United States
Chapel Hill, North Carolina 27516, United States
Caba, Buenos Aires C1425DES, Argentina
Ciudad Autonoma Buenos Aires, C1055AA0, Argentina
Ciudad Autonoma Buenos Aires, C1425BEA, Argentina
Ciudad Autonoma Buenos Aires, C1425DKG, Argentina
Ciudad Autonoma Buenos Aires, C1430EGF, Argentina
Ciudad Autonoma de Buenos Aire, C1122AAF, Argentina
Ústí nad Labem, Ustecký Kraj 40113, Czechia
Bad Bentheim, North Rhine-Westphalia 48455, Germany
Inashiki-gun, Ibaraki 300-0395, Japan
Nagaski, Nagaski 852-8501, Japan
Nakagami-gun, Okinawa 903-0215, Japan
Ohtsu-shi, Shiga 520-2192, Japan
Bunkyo-ku, Tokyo 113-8655, Japan
Chuo-Ku, Tokyo 104 8560, Japan
Itabashi-ku, Tokyo 173 8606, Japan
Itabashi-ku, Tokyo 173-8610, Japan
Shinagawa-ku, Tokyo 142-8666, Japan
Shinjuku-ku, Tokyo 160-0023, Japan
Bialystok, Podlaskie Voivodeship 15-375, Poland
IlsanSeo-gu, Goyang-si 10380, South Korea